Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis

NCT02102204 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02102204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02102204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
March 25, 2014
Completion date
June 26, 2017
Enrollment
902 (actual)
Sites
228

Conditions

As the registry lists them; a condition with its own page is linked.

hyperparathyroidism, secondary